Nurix Therapeutics Inc (NAS:NRIX)
$ 15.9 0.95 (6.35%) Market Cap: 970.97 Mil Enterprise Value: 698.12 Mil PE Ratio: 0 PB Ratio: 4.35 GF Score: 67/100

Nurix Therapeutics Inc at Robert W Baird Global Healthcare Conference Transcript

Sep 13, 2022 / 02:50PM GMT
Release Date Price: $15.76 (-3.25%)
Unidentified Analyst

Joining our next session with Nurix Therapeutics, I'm really pleased to have with us Arthur Sands, who is President and CEO of Nurix. To begin, Arthur has some prepared slides, and then we'll jump into some Q&A afterwards. Arthur, thanks for joining us.

Arthur Sands
Nurix Therapeutics, Inc. - President, CEO, & Board Director

Thank you, sure. Thank you very much. So Nurix is a leader in Targeted Protein Modulation. We developed small molecules that can modulate protein levels. Of course, I'll be making certain forward-looking statements. Refer to our filings with the SEC.

So what do we mean by Targeted Protein Modulation, as pictured here? So at all -- the center of our system is the E3 ligase enzyme system, which is pictured at the center of the slide. And this is a class of enzymes within the cell. There's over 600 of them encoded in the human genome. And they all have very specific functions.

And what they do is they ligate on a ubiquitin moiety -- which is pictured here in green, that little green peptide -- onto

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot